Icon (ICLR) Expected to Announce Earnings on Wednesday

Icon (NASDAQ:ICLR) is projected to issue its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect Icon to post earnings of $3.28 per share and revenue of $1.9848 billion for the quarter. Icon has set its FY 2025 guidance at 13.000-14.000 EPS.Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The company had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the prior year, the business posted $3.75 EPS. The business’s revenue was down 4.8% compared to the same quarter last year. On average, analysts expect Icon to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Icon Price Performance

NASDAQ:ICLR opened at $185.06 on Monday. The stock has a market capitalization of $14.95 billion, a PE ratio of 19.04, a P/E/G ratio of 2.75 and a beta of 1.23. Icon has a 1-year low of $125.10 and a 1-year high of $301.45. The firm has a fifty day simple moving average of $177.18 and a 200 day simple moving average of $157.27. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35.

Hedge Funds Weigh In On Icon

Several institutional investors and hedge funds have recently made changes to their positions in the company. Harris Associates L P bought a new stake in shares of Icon in the second quarter valued at about $238,256,000. Balyasny Asset Management L.P. acquired a new stake in Icon in the 2nd quarter worth about $94,814,000. Ruane Cunniff & Goldfarb L.P. boosted its holdings in Icon by 36.2% in the 2nd quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company’s stock valued at $248,455,000 after purchasing an additional 453,833 shares during the period. Orbis Allan Gray Ltd acquired a new position in shares of Icon during the 2nd quarter worth approximately $48,824,000. Finally, BNP Paribas Financial Markets grew its position in shares of Icon by 147.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 487,409 shares of the medical research company’s stock worth $70,894,000 after purchasing an additional 290,258 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Rothschild & Co Redburn raised shares of Icon from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $184.00 to $236.00 in a research report on Wednesday, September 3rd. UBS Group raised their target price on shares of Icon from $170.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Robert W. Baird boosted their price target on Icon from $222.00 to $224.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Mizuho raised their price objective on Icon from $173.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Finally, Evercore ISI boosted their target price on Icon from $170.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $210.64.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.